Therapeutic effects of PEGylated insulin-like growth factor I in the pmn mouse model of motoneuron disease

► New translational approach for IGF-I therapy in motoneuron diseases. ► Improved drug properties for IGF-I without loss of biological activity relevant for neuromuscular disorders. ► Systemic IGF-I exerts central neuroprotective effects on motoneurons. ► Neuroprotection correlates with functional benefits in pmn mice.